247148-40-9

Basic information

• Product Name: N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]acetamide
• Synonyms: N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]acetamide
• CAS NO: 247148-40-9
• Molecular Formula: C₁₉H₁₅N₃O₃
• Molecular Weight: 333.3407
• Mol File: 247148-40-9.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]acetamide(247148-40-9)
• EPA Substance Registry System: N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]acetamide(247148-40-9)

Safety Data

• Hazardous Substances Data: 247148-40-9(Hazardous Substances Data)

Upstream product

• 247149-95-7 N-[2-(4-methoxy-benzoyl)-1,3-dioxo-indan-4-yl]-acetamide 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 13365-26-9 dimethyl 3-nitrophthalate 
• 34529-06-1 dimethyl 3-aminophthalate 
• 60-35-5 acetamide 

Downstream Products

• 247148-41-0 2-chloro-N-[3-(4-methoxyphenyl)-4-oxo-2,4-dihydroindeno[1,2-c]pyrazol-5-yl]acetamide 
• 247148-86-3 3-(4-methoxyphenyl)-5-(formamido)indeno[1,2-c]pyrazol-4-one 

Relevant articles and documents

Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors [1]

-

Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents

The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula (I): that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and their regu

Indeno [1,2-c] pyrazol-4-ones and their uses

The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula (I): that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-9 and their regulatory subunits know as cyclins A-H. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.